The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis.
We studied the usefulness of topical cysteamine ophthalmic drops in reducing crystal formation within the corneas of patients affected by nephropathic cystinosis. A dosage of 0.3% cysteamine given four times daily was chosen as a more manageable method than a previously reported protocol of hourly administration of 0.11% drops. No reduction in crystal formation was observed in our patients; they were followed for seven months.
MacDonald
I M
IM
Department of Biochemistry, University of Ottawa, Ontario, Canada.
Noel
L P
LP
Mintsioulis
G
G
Clarke
W N
WN
D000287:Administration, Topical; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology; D003460:Crystallization; D003543:Cysteamine / Q000008:administration & dosage / Q000627:therapeutic use*; D003554:Cystinosis / Q000150:complications*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D011379:Prognosis; D014792:Visual Acuity
D003543:Cysteamine